The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate.
Since it has been reported by several authors that colestipol HCl and clofibrate have an additive effect in lowering serum cholesterol levels, it was felt advisable to evaluate the blood levels of clofibrate when given simultaneously with colestipol HCl to see whether there was any evidence for drug interaction between the two products that might dictate a need for separation of their administration time. After concomitant single-dose administration, the serum p-chlorophenoxyisobutyric acid levels, bioavailability parameters, and pharmacokinetic parameters investigated provided no evidence for an interaction and suggested that colestipol and clofibrate can be administered concomitantly or at separated in tervals according to whichever dosage regimen is deemed advisable by the physician.
D000328:Adult; D001682:Biological Availability; D002994:Clofibrate / Q000097:blood / Q000378:metabolism*; D003084:Colestipol / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D008297:Male; D011073:Polyamines / Q000494:pharmacology*; D013997:Time Factors
D011073:Polyamines; D002994:Clofibrate; D003084:Colestipol